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Introduction
Cancer is the second leading cause of death worldwide, taking 
the lives of over 8.2 million people every year. The standard can-
cer treatments, such as chemotherapy and radiation therapy, are 
often inadequate and debilitating, destroying healthy fast-grow-
ing cells in the process of treatment.  Over the past decade, 
gene therapy has become a more prevalent option for treating 
cancers.  Gene therapy avoids targeting healthy cells, selecting 
only cancerous cells for treatment.  There are three approaches 
to gene therapy immunotherapy: stimulating a patient’s immune 
system to recognize and attack cancer cells, oncolytic virother-
apy, which generally uses viruses to infect and kill cancer cells, 
and gene transfer, which is the insertion of genetic material into 
the cancerous cells.  This paper aims to consider the viability of 
gene transfer therapy. Gene transfer therapy is an exciting new 
technology that is shifting the paradigm of cancer treatment. 
It involves inserting a foreign gene directly into the cancerous 
cells or surrounding tissue’s genome (Cross, Brumester 2006). 
With all the strides and progress made in gene transfer there 
???????????????????????????????????????????????????????????????????
cases, gene transfer scared many by causing the death of a pa-
tient (Raper, et. al. 2003).  Also, in some cases, gene transfer 
methods have promoted leukemia in their attempt to cure the 
patient of his disease (Thomas, et. al. 2003). Additionally, there 
is still plenty of research yet to be done in this area due to its 
relative newness.   This paper will assess how much of an option 
gene therapy is for cancer patients, taking into account its nu-
????????????????????????? ?????????????????????
Methods
Research literature for this paper was obtained through the 
Touro College Online library. Searches done on the Touro 
College Online library led the student to Proquest and Pubmed, 
where majority of the articles were obtained. Articles found on 
other scholarly sites were also used.  The articles discussed ex-
perimental studies done and the thorough analysis of these ar-
ticles allowed for the assessment of gene therapy’s practicability. 
Review articles also assisted in composing the formal analysis.  
Discussion
The standard treatment method for cancer today is chemother-
apy. Chemotherapy can cause an array of both short term and 
long term side effects. Short term side effects are side effects 
that are present during the time of treatment and are often 
reversible, while long term side effects cause more severe and 
permanent damage.  Short term side effects include hair loss, 
nausea, and vomiting, which can sometimes hinder patient com-
pliance. Long term side effects such as arthritis, appendicitis, 
and thyroid damage have less of a probability of occurring, but 
do occur in some patients (Ramirez, et. al. 2009). The above 
mentioned are general side effects, but each patients’ individual 
circumstance can pose other possible risks.  If patients could be 
assured that chemotherapy would remove the cancer in totality, 
undergoing chemotherapy would be more tolerable, yet in many 
cases the chemotherapy fails to rid the body from the cancer 
and therefore, is often not a preferable option.
In this paper, gene therapy will be analyzed to assess whether 
it is a better option of treatment for cancer patients or whether 
it is yet another treatment method that provides partial results 
????????????????????????????????????????????????????????????????
treating cancer, what side effects it includes and what the severi-
ty of the side effects are all questions that need to be addressed.
Insertion Approaches
There are two approaches to gene insertion; it can be done 
by means of either a viral or a non-viral vector (Amer, 2014). 
A viral insertion uses a virus as a vector to harbor the drug. A 
non-viral vector, which generally uses naked DNA or toxic ma-
terial for the cell as a vector, can be inserted either chemically 
or physically. Physical insertion can be done by a gene gun or 
ultra sound.  Another physical approach is that of electropora-
tion, which uses high voltages of electricity to disrupt the cell’s 
membrane, allowing the drug to enter the cell (Baranyi, et. al. 
2013).
Viral Insertion
Viruses have long been a choice for a vector because of some 
important properties they contain.  Viruses are small pathogenic 
particles that contain either DNA or RNA encoded in a protein 
coat.  Some viruses also contain a lipid bilayer surrounding the 
protein coat.  The mechanism in which a virus infects a cell is 
by implanting itself on the host cell’s membrane and inserting 
its viral DNA into the host cell. The host cell then transcribes 
and translates the viral DNA, which codes for the creation and 
Abstract
????????????????????????????????????? ?????????????????????????? ???????????????????????? ???????????????????????????????????
??????? ???????????????????????? ?????????? ???????????????????????????????????????????????????????? ? ?????????????????????????
negative outcomes on patients gave gene therapy a bad name and many began skeptical towards its use, but the constant work 
and progress on the safety and effectiveness of gene therapy is making it a more viable route of treatment. This paper focuses 
??????????????????????????????????????????????? ???????????????????????????????????????????????????????????????????????????????
insertion, targeting a large number of cells, although physical insertion may be safer and more economical.  The mechanism by 
which many gene therapies work is suicide genes, genes that cause the cell they enter to lyse.  The paper goes on to discuss the 
??????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
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promising results for many cancer patients.
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assembly of more viral particles.  These new viruses cause the 
cell to burst and proceed to infect more cells. The mechanism 
by which the virus operates is useful, for genetic material that 
will lead to cancer cell death or degeneration can be placed 
in a virus vector, which is essentially the outer protein coat of 
the virus deprived of its viral genome, and then infect the tar-
get tissue area.  Before using it as a vector, the virus has to be 
rendered non replicative so it no longer behaves as a pathogen. 
Viral vectors are advantageous since they can be produced in 
high concentrations and have minimal side effects (Amer, 2003).
The most popularly used viral vector is the adenovirus. The 
adenovirus is favored since it can be made in high titers and can 
infect both dividing and non-dividing cells. When using a viral 
vector such as the adenovirus, steps must be taken to ensure 
that the virus will not reproduce in the host’s body like it nat-
urally would. Prevention of the adenovirus replication can be 
achieved by removing early regions of the adenovirus vector’s 
genome (Pulkkanen, et. al. 2005).
Comparing Adenovirus to Retrovirus
?????????????????????????????????????????????????????????????-
virus as vectors for gene transfer was done.  Ten patients with 
malignant glioma, a spreading brain tumor, were treated with a 
beta galactosidase gene via retrovirus and adenovirus vectors. 
This was done by inserting a catheter into the tumor and in-
jecting the patient with retroviruses and adenoviruses for three 
consecutive days.  This was followed by resection of the tumor 
one to two days later.  X-gal staining was then used to highlight 
????????????????????????????????????????????????????????????????
transfer. Findings showed that beta galactosidase was well tol-
erated with both vectors.  In all but two patients, no systemic 
or tissue complications were apparent.  The gene transfer was 
????????????????????????????????????????????????????????????????
???????????????????????? ???? ???????????????? ????????????????
??????????????????????????????????????????????????????????????
vector (Puumalainen, et. al. 1998).
Malignant Glioma Adenoviral Gene Therapy
???????????????????? ????????????? ???????? ??????????????????????
of gene transfer amongst other viral vectors, they still fall short of 
?????????????????????????????????????????????????????????? ??????????
the treatments of malignant glioma was conducted with the aim of 
evaluating the safety of the adenoviral vector as well as determining 
the maximum possible dose that would be tolerated. Fourteen pa-
tients with relapsed malignant glioma were treated with adenoviral 
vector containing the Herpes simplex virus thymidine kinase (HSV-
tk) and its promoter (IG.Ad.MLPI.TK), and were then treated with 
ganciclovir, an antiviral drug.  Prior to this the retrovirus had been 
used as a vector for HSV-tk gene therapy treatment.  However, the 
adenovirus was used in this study because of its advantages of high 
???????????????????????????????????????????????
The patients underwent as much debulking of the tumor as 
????????????????????????????????????????????????????????????
around 50 evenly spaced injections of the HSV-tk gene.  The 
patients were treated with different dose levels and then mon-
itored for any adverse events.  The patients reported either 
adverse events or serious adverse events.  From surgery until 
completion of the ganciclovir treatment, 27 adverse events and 
5 serious adverse events were reported. However none of the 
adverse events or serious adverse events were from the ade-
noviral vector.
After surgery, the patients were kept in strict isolation in the 
ICU, and viral cultures were taken until there were two consec-
utive days of negative culture results. None the cultures taken 
were found to be positive, indicating that the viral vector did 
not shed during its administration and did not pose a hazard to 
the environment. 
The adenovirus was thus considered to be a safe vector in-
ternally and externally.  However, in regard to the results of the 
patients’ tumor responses, the adenovirus does not appear as 
promising.  Unfortunately, none of the tumors responded to the 
successful gene transfer.  Overall the patients did not fare well. 
The median survival time was four months, with four patients 
surviving for over a year.  The median survival time attained in this 
study with the injection of the adenoviral vector was no better 
than the survival time in respective studies of malignant glioma 
with no gene therapy treatment.  According to the study, even the 
survival of patients with the favorable prognosis was most likely 
due to the nature of the tumor and not the gene transfer.
It is clear that the adenoviral vector used in this study is a 
?????????????????????????????? ??????????????????????? ????? ??-
????????????????????????? ??? ????????????????? ???????????????? ???
the adenoviral gene transfer had even any effect on the tumor. 
(Smitt, et. al. 2003).
In contrast to viral vectors, non-viral vectors are generally 
more economical and easier to produce in large quantities. They 
also have limited immunogenicity which allows for re-dosing. 
There is no concern of a gene recombination causing the virus 
to become competent and pose a danger to the body (Amer, 
et. al. 2014).
Physical Insertion
Physical insertion involves injecting naked DNA or liposomes 
directly into the target cell through a breach in the membrane 
made by rapid needle or jet injections, particle impact, electric 
pulse, laser radiation, or ultrasound. A novel method of physical 
??????????????????????????????????????????????????????????????????
as an alternate to needle injections. Jet injection uses a pres-
??????????????????????????????????????????????????????????????????
stream of DNA into the target tissue in the form of plasmids. 
Comparisons done between jet and needle injections demon-
???????? ????? ????? ??????????? ???? ????? ?? ??? ???????? ?????
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done by jet injection than it was done by the standard needle 
injection. 
A phase 1 study was conducted to determine the safety and 
feasibility of jet injection on patients with skin metastases from 
????????????????????????????????????????????????????????????????
injections of B-galactosidase, a LacZ- expressing DNA plasmid, 
into a single cutaneous lesion.  To monitor the clearance of the 
plasmid in the blood stream, real time quantitative PCR of blood 
samples was done throughout the study.  After two to six days, 
the lesions were resected and a series of tests were performed 
?????????????????????????????????????????????????????????????????
transcription of DNA to mRNA and translation to a protein.  
All the patients responded well to the jet injections.  Four 
weeks after jet injection, all the patients were alive and none 
showed any adverse effects from the jet injection.  Within 
forty-eight hours any small bleeding and jet penetration at 
the injection site disappeared.  Additionally, the LacZ plasmids 
were successfully taken up by all the tumors, with variation in 
amounts detected in each tumor (Wolfgang, et. al. 2008).
Because this was a phase 1 study, research was taken to de-
termine the safety of the jet injection and did not cover the 
???????????????????????????????????????????????????????? ????????
gene did not have any association to reduction of cancerous 
growth, but rather served as a marker to determine if jet injec-
tion was a viable method of gene transfer.  Research on humans 
using jet-injection-based gene transfer as antitumor therapy is 
limited and quite recent. There have been studies done on mice, 
though, with encouraging results. 
A study was conducted on mice containing human colon carcino-
ma to test the effectiveness of gene transfer jet injection in its ability 
to inhibit tumor growth.  The mice were injected four times with 
a suicide gene, Escherichia coli cytosine deaminase, and then after 
???????????????????????????????????????????????????????????????????
?????????????? ???? ????????????????????????????????????????? ???
?????????????????????????????????????????????????????????????????????
injected suicide gene in comparison to the control groups’ tumors. 
Additionally, protein and mRNA levels revealed that the suicide 
???????????????????????????????? ??????????????????????
Although this study was not conducted on humans, it still has 
???????????????????????????????????????????????????????????????????
genes is an alternate method to injection via viral vectors, with 
comparable therapeutic response.  Though there are studies, as 
mentioned above, of successful adenoviral vector gene transfers, 
the adenoviral vector does have limitations that the jet injection 
does not.  When using the adenovirus as a vector, there is always 
the concern that it may have a pathogenic effect on the patient, 
or that the patient’s immune system will respond to the viral 
proteins and inhibit the vector in completing its task.  Jet injec-
tion looks promising for cancer treatment, but it is only useful 
for subcutaneous cancerous growths, like that of melanoma and 
breast cancer, since it cannot penetrate very deep. 
Suicide Genes
Once the genetic material is successfully transferred into the 
host cancer cells and incorporated into the nuclear genetic 
DNA, there are a few methods by which it represses tumor 
growth.  A key method being the injection of suicide genes, 
which are genes that cause apoptosis, or cellular death, when 
expressed.  These genes are usually transcribed by various pro-
moters found within the host cell. The H19 RNA gene is an 
example of one such promoter.  The H19 gene locus was the 
?????? ???????????????????????????????????????????????????????
study has been done on the role of the H19 gene and tum-
origenesis.  It is found that there is an abnormal expression 
of the H19 RNA gene in many cancerous cells, causing cancer 
cell proliferation, genetic instability, vascular angiogenesis, and 
tumor metastases.  In a number of studies, blocking the H19 
gene led to tumor regression and necrosis (Amer, et. al. 2014).
H19 Locus and tumorigenesis
The H19 RNA gene is greatly expressed in fetal organs but 
is rapidly turned off at birth.  In tumor cells, the H19 gene 
becomes highly expressed or shows an abnormal expression 
pattern when compared to normal non-cancer cells.  In cancer 
cells, the H19 gene expression can be activated by a combina-
tion of various transcriptional modulators and regulators that 
have malfunctioned.  The interplay of the H19 gene locus and 
the modulators in tumorigenesis is highly complex, involving 
many regulatory factors that rely on many other regulatory 
factors (Matouk, et. al. 2013).
Hypoxia and H19
One such approach to the H19 gene’s upregulation in can-
cerous cells is through hypoxia.  Hypoxia is the loss of oxy-
gen to areas of cancerous growth, and is considered a major 
trigger for metastasis, tumor angiogenesis, and chemotherapy 
resistance.  Hypoxia is also considered to increase H19 ex-
pression in tumor cells.  A study was done to investigate the 
relation between hypoxia and H19 upregulation in tumor cells. 
Carcinoma and Hepatocellular carcinoma cell lines were placed 
in an Aneropack rectangular jar and supplemented with Gaspak 
to create a hypoxic environment.  Some cells where left with 
normal oxygen conditions as a control.  The cells were then 
monitored by a hypoxic indicator.  After twenty-four hours, the 
cells were examined and RNA from each cell was extracted and 
??????????????????????? ????????????????????????????????????-
???????????????????????????????????????????????????????????
than the cells under normal oxygen conditions. 
In a similar study, mice were injected with Hep3B, cells contain-
ing hepatitis B, which caused the proliferation of Hepatocellular 
carcinoma on their dorsal side.  A group of those mice were 
then injected with siRNA, a H19 gene knockout.  The results 
showed that the mice that were treated with the siRNA showed 
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????????????????????????????????????????????????? ???????????????
study it is clear that H19 plays a large role in tumor growth, and 
is activated by hypoxia, which is common in cancerous growths 
(Matouk, et. al. 2007, Matouk, et. al. 2005).
c-Myc and H19
Another factor that induces H19 transcription is the c-Myc 
transcription factor.  C-Myc is a transcription factor that, to-
gether with its obligate partner, protein Max, another transcrip-
tion factor, binds to E-boxes, which are enhancer sequences on 
the DNA that initiate transcription. C-Myc then promotes gene 
transcription by initiating chromatin remodeling on the DNA 
or RNA polymerase clearance.  To assess the role of c-Myc in 
tumor cells with increased H19 expression, a study was de-
signed in which c-Myc was inserted into breast and glioblastoma 
cell lines.  Cells inserted with c-Myc showed a seven-fold to 
ten-fold increase of H-19 expression based on Real-time PCR 
readings. Breast and lung cancer cell lines were also used to 
determine the correlation between elevated levels of c-Myc 
and H19 and tumor growth.  The cell lines containing elevated 
levels of H19 and c-Myc were treated with siRNA to knock 
down H19 expression.  The cells with knockdown H19 exhib-
????? ??????????? ???????????? ??? ????????????????????? ??????????
established as another factor that induces H19 upregulation and 
thereby increases tumor growth (Barsyte, et. al. 2006).
E2F1 and H19
Another basis for increased H19 expression in cancer cells is 
the E2F1 regulatory factor. E2F1 belongs to the E2F protein 
family that regulates DNA by binding to promoters.  E2F1 binds 
to the H19 promoter and initiates its transcription. E2F regula-
tion is based on the stages of the cell cycle. E2F1 is considered 
a key factor in the transition from G1 to S in the cell cycle, as 
it promotes the transcription of genes whose protein products 
are necessary for the progression of the cell cycle and for imi-
tating DNA duplication.  Thus, increased E2F1 expression when 
it is not the appropriate cell stage or time for cell replication 
can lead to cancerous growths.  
A study conducted assayed the correlation between increased 
E2F1 and H19 gene expression in the S phase, as well as E2F1’s 
impact on tumor growth.  First, epithelial breast cells were 
transfected with a luciferase reporter gene, a selectable marker 
gene that, when expressed, causes the cells to emit a biolumi-
nescence. Half of the cells were transfected with a luciferase re-
porter gene carrying the wild type H19 gene and the other half 
with a mutated promoter site of an H19 gene, so E2F1 binding 
is inhibited.  The breast cells were then serum starved, and after 
twenty-four hours, some cells were placed in a fresh medium to 
stimulate their entry into cell cycle.   After a set time, the cells 
??????????????????????????????????????????????????????????????
intensity test, because the luciferase reporter that was used 
contains bioluminescence.  Results showed that serum-starved 
cells had very little H19 expression, while cells in S phase had 
remarkably increased levels of H19.  The cells transfected with 
the mutated promoter site had low H19 expression compared 
to the wild type cells that had overall increased H19 expression, 
especially at S phase (Fig. 1).  
The correlation between H19 and E2F1 binding to its pro-
moter is demonstrated when the comparison between the wild 
type and mutated transfected cells are noted. The cells with wild 
type H19 promoter sites showed a higher concentration of lu-
ciferase activities, since E2F1 was able to bind to the promoter 
site and activate transcription, while the cells with the mutated 
promoter sites exhibited a lower concentration of luciferase 
activities since E2F1 was not able to bind to the mutated pro-
??????????????? ???????????????????????????????????????????????????
phase is observed by the fact that the greatest percentage of 
cells were recorded during the S phase of the cell cycle. 
????????????????????????????????????????????????????????????????????
?????????????????? ??????????????????????????????????????
????????????????????????????????? ????????????????????????????
?????????????????????????????????????????????????????????????????????
than the mutated cells.  
B. Shows the percentage of cells distributed throughout the cell 
????????????????????????????????????????????????????????????????
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The second step of the study was to examine the roles of 
H19 and E2F1 in cancer proliferation.  Breast cancer cell lines 
were obtained and the levels of E2F1 mRNa and H19 RNA were 
calculated.  Normal breast cells were used as a control. The data 
showed that the expression of E2F1 and H19 were generally 
corresponding.  In the healthy breast cells there were low levels 
of both E2F1 and H19 expression, while most of the cancer 
cells showed notable activation of E2F1 and H19 gene. In one 
line of cancer cells however, the E2F1 expression was high but 
the H19 expression was comparatively low. This discrepancy 
was attributed to heterogeneity of breast tumors.  In general, 
there is a correlation between E2F1 and H19 upregulated gene 
expression in cancerous tissue (Berteaux, et. al. 2005).
Based on the studies discussed above, increased H19 ex-
pression is regulated by a number of regulatory factors, such as 
c-Myc and E2F1.  Their upregulation is also triggered by environ-
mental stress conditions such as hypoxia and S phase induced 
cells after serum starvation.  However, cells under normal con-
?????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????
upregulated in many cancer cells, for hypoxia and serum starva-
tion are considered normal stages in tumor growth.  Thus, the 
tumor’s growth causes its further proliferation. As it outgrows 
??????????????????????????????????????????????????????????????-
ygen and reside in hypoxic microenvironments, which in turn 
triggers the increased expression of H19, further promoting 
cancerous growth.
Some of the explanations of H19 gene upregulation in tumor 
cells have been presented, and the therapeutic methods involv-
ing the H19 locus will now be discussed.
BC-819 Gene Therapy
In the past couple of years, BC-819, a plasmid involving a suicide 
gene and the H19 promoter, has been developed and has suc-
cessfully improved treatment of a number of cancers.  BC-19 is 
a double-stranded DNA vector that contains Diphtheria toxin 
A sequence, which isused to destroy the cancer cell, and an H19 
promoter sequence. It is mixed with Polyethylenimine transfec-
tant (PEI), which allows for easier entry of the plasmid into the 
rapidly dividing tumor cells.  In some cases, PEI is not used and 
BC-819 is injected intratumorally or by hepatic artery infusion 
(Matouk, et. al. 2013).
Once BC-819 is in the cancer cell, the H19 promoter is ac-
tivated and transcribed continuing with the Diphtheria toxin A 
sequence, which causes cell death by disrupting protein syn-
thesis.  BC-819 can actively select tumor cells to destroy, since 
only tumor cells have increased levels of H19 transcriptional 
factors.  BC-819 will enter healthy cells as well, but since they 
lack the H19 regulatory factors, they will not transcribe the 
plasmid and the cells will not be destroyed.  BC-819 is an in-
genious development that acts as a ‘search and destroy’ unit by 
only killing cells that contain H19 transcriptional factors thereby 
triggering their own demise (BioCanCell, 2017).  BC-819 has 
been semi-successful at treating bladder, pancreatic and ovarian 
cancer patient (Fig. 2)s. 
Bladder Cancer
In the United States, bladder cancer is the fourth most com-
mon cancer in men, with an estimated 74,000 annual incidents. 
Around 70% of bladder cancer patients suffer recurrence within 
??????????? ????????????????????????????????????????????????????????
its recurrence.  For decades, the standard care option was the 
BCG vaccine but the vaccine included drawbacks such as re-
currence, resistance to the treatment, and negative side effects 
(Matouk, et. al. 2013).
?????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????
recurrent bladder cancer and for whom BCG and chemother-
apy had failed were recruited and BC-819 with PEI was admin-
istered to them.  First, they were given six weekly treatments 
??????????? ?????????????????? ???????????????????????? ?????????
were assessed. In cases of no toxicity or recurrence therapy 
was discontinued in patients and follow up maintenance therapy 
???????????????????????????????????????????????????????????????
nine out of eighteen patients had complete resolution of the 
target lesion within eight to ten weeks.  Overall, 63% of pa-
??????? ???? ???????????????? ??????? ???? ????????? ?????????????
after treatment and 48% had tumors for a year after treatment. 
Additionally, the patients tolerated the treatment well with only 
mild to moderate adverse effects. 
Reports of Phase III trials have not yet been published but 
trials are in progress as of the year 2016.
Pancreatic Cancer 
The eighth leading cancer cause of death in the United States 
??????????????????????????????????????????????????????????????????
The standard treatment for pancreatic cancer is gemcitabine, 
a chemotherapy drug. However, gemcitabine has limited effect 
because of its poor intracellular metabolism. Other methods 
have been tried in combination with gemcitabine in the hope 
of a more effective treatment, but none proved worthwhile. 
Recently, BC-819 and gemcitabine were tested together on pan-
creatic patients in a phase 2b study that showed more promising 
results. Patients received four week treatments of gemcitabine 
???????????????????????????
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and were then administered with BC-819 through endoscopic 
ultrasound.  Continued treatment with gemcitabine and BC-819 
was done for as long as the cancerous growth did not progress. 
After three months, nine out of eleven patients showed en-
couraging results.  Two had partial recovery and seven reached 
a point of stable disease. There were several adverse events 
mostly relating to liver function, but it was concluded that the 
adverse events were not related to the BC-819 , but were rath-
er due to the advanced stage of the cancer that all the patients 
had (Matouk, et.a. 2013).
Ovarian Cancer 
For women, ovarian cancer has a high mortality rate and is the 
?????????????????????????????????????????????????????????????????
Ovarian cancer patients generally have a poor prognosis, because 
the initial detection of the cancer is usually after it has reached an 
advanced stage.  The typical course of treatment includes surgical 
removal of the tumor followed by chemotherapy.  Unfortunately, 
most patients with the advanced stage tumor experience re-
????????????????????????????????????????????????????????????????????
?????????????????????????? ?????????????????????????????????????
plasmid was conducted on fourteen ovarian cancer patients.  All 
fourteen women had been pretreated with extensive chemother-
apy.  Different doses of BC-819 were administered to different 
????????????????????????? ????????????????????????????????????????
for three weeks with BC-819, rested for a week, and were then 
treated for six more consecutive weeks. This was followed by a 
four week rest period. The second and third cohort were treat-
ed with increased dosages for three weeks, with four weeks of 
rest and then an attempt at repeat treatment when possible. Of 
the fourteen subjects, only 3 completed the study, while the rest 
withdrew prematurely due to overall clinical deterioration.  There 
???????????????????????????????????????????????????????????????
?????????? ????????????? ????????? ???? ??????????????? ??????????
possibly related to BC-819 administration.  The best outcome of 
??????????????????????????????????????????????????????????????????
growth to qualify as either a partial response or progressive dis-
ease.   The patients in the study all had advanced tumor growth, 
???? ???? ???????? ???????? ?????????? ????? ????????? ?????? ????????
cancer, BC-819 treatment would yield a partial response (Lavie, 
et. al. 2017).
BC-819 shows great promise for cancer patients. Although 
not every patient treated in the studies mentioned above had 
a positive outcome from the treatment, no one’s medical state 
was worsened.  The study of the BC-819 treatment is still in 
progress. The studies mentioned above are phase one or two 
studies, which means they are being done to determine the 
???? ??????????????????????????????????????????????????????????? ?
??????????????????????????????????????????????????????????????????
drug can be open to the public. A phase three trial is presently 
ongoing for bladder cancer, and a phase one/two has been com-
pleted for ovarian and pancreatic cancer.
Based on the various studies presented, gene therapy appears 
to be a viable option for cancer treatment.  Although in each 
study there were some patients who did not fare well with this 
form of treatment, as an overall option, gene therapy looks like 
a promising alternative for cancer patients for whom standard 
???????????????????????????
Gene Therapy and Leukemia
However, there have been studies that have shown that in its 
attempt to rid the patient of his illness, gene therapy can actually 
promote one of the deadliest cancers, leukemia. 
In 2002, a group of infants with severe combined immunode-
???????????? ??????????????????????????????????????????????????
????????????????????????????????????????????????????????????????
This alarmed many patients and researchers, and was a major 
setback in the advancement of gene therapy.  
SCID is caused by a genetic mutation, making a patient with 
it lack the IL-2 receptor ? (IL2RG) gene. To restore the absent 
gene, the infants in the study were treated with a therapeu-
tic gene via a retroviral vector.  However, the retroviral vector 
works by inserting its genome near a transcription start site 
in the host genome, allowing the virus’ long terminal repeats, 
which are repeated identical sequences of DNA that enable 
insertion into the host genome, to unintentionally  turn on 
transcription of other nearby sites. In these infants with SCID, 
the LMO2 oncogene site was found near the insertion site and 
was turned on, promoting leukemic growth (Hacein-Bay-Abina, 
et.al. 2008).
The events of this gene therapy treatment were unfortunate, 
and did remove some of the enthusiasm for gene therapy at the 
time.  However, the fact that this occurred on SCID patients and 
not on cancer patients must be taken note of, thus gene therapy 
might not be the right choice for SCID patient, but that does 
not rule out cancer patients.  Cancer patients may not have an 
oncogene site near the insertion site for their therapeutic gene, 
which completely removes the possibility of inducing leukemia. 
In the research done, no reports have been made demonstrat-
ing that gene therapy for cancer patients further induced new 
cancerous growths. 
Conclusion
Although gene therapy as a treatment option for cancer has 
had some setbacks and inconclusive results, it still provides 
a large source of hope for cancer patients.  The paradigm of 
treating cancer is slowly shifting due to the ongoing progress 
of gene therapy.  Based on the studies presented above, overall 
gene therapy, whether administered through a viral vector or 
a non-viral vector, was successful in treating a portion of the 
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patients.  Additionally, even in the studies done in which small or 
no substantial recovery was obtained, there were no consider-
able adverse effects on the patients treated with gene therapy. 
This greatly contrasts standard treatments like chemotherapy 
that cause an array of adverse effects on the patient without 
necessarily providing complete removal of the cancer.  Thus, 
even though gene therapy may not provide a complete cure 
against cancer, it is a promising alternative to standard cancer 
treatment.  With the constant hard work and progress of medi-
cal researchers and physicians that is presently taking place, it is 
anticipative to say that gene therapy will provide great relief to 
many cancer patients in the coming years.
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